MedPath

Bimatoprost in the Treatment of Eyelash Hypotrichosis

Phase 3
Completed
Conditions
Idiopathic Eyelash Hypotrichosis
Interventions
Drug: bimatoprost formulation A solution
Drug: bimatoprost solution 0.03 %
Drug: vehicle of bimatoprost formulation A solution
Drug: vehicle of bimatoprost solution 0.03 %
Registration Number
NCT01698554
Lead Sponsor
Allergan
Brief Summary

This study will evaluate the safety and efficacy of bimatoprost solution formulation A compared with bimatoprost solution 0.03% (LATISSE®) and vehicle in the treatment of eyelash hypotrichosis (inadequate eyelashes).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
464
Inclusion Criteria

-Male and female adult patients with eyelash hypotrichosis (inadequate eyelash growth).

Read More
Exclusion Criteria
  • Damage to eyelid area (scarring) that may prevent growth of eyelashes
  • Active eye diseases (glaucoma, uveitis, eye infections, chronic blepharitis or severe dry eye)
  • Eye or eyelid surgery (including laser, refractive, intraocular filtering surgery, blepharoplasty) during the 3 months prior to screening
  • Current eyelash implants of any kind
  • Eyelash tint or dye application within 2 months of baseline
  • Eyelash extensions application within 3 months of baseline
  • Use of eyelash growth products within 6 months of baseline
  • Treatments that may affect hair growth (minoxidil, cancer chemotherapeutic agents, etc) within 6 months prior to baseline.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
bimatoprost formulation A solutionbimatoprost formulation A solutionBimatoprost formulation A solution single-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
bimatoprost solution 0.03 %bimatoprost solution 0.03 %Bimatoprost solution 0.03 % (LATISSE®) multi-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
vehicle of bimatoprost formulation A solutionvehicle of bimatoprost formulation A solutionVehicle of bimatoprost formulation A solution single-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
vehicle of bimatoprost solution 0.03 %vehicle of bimatoprost solution 0.03 %Vehicle of bimatoprost solution 0.03 % multi-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
Primary Outcome Measures
NameTimeMethod
Percentage of Participants With at Least a 1-Grade Increase (Improvement) From Baseline in the Investigator's Assessment of Overall Eyelash Prominence (GEA)Baseline, Month 4

The investigator evaluated the overall eyelash prominence in both eyes using the GEA 4-point scale: 1= minimal, 2= moderate, 3= marked and 4= very marked. A 1-grade improvement in the GEA score from Baseline indicated improvement.

Secondary Outcome Measures
NameTimeMethod
Change From Baseline in Upper Eyelash Thickness/Fullness as Measured Using DIABaseline Month 4

Photographs were taken of the eyelashes and assessed using DIA. Eyelash thickness (fullness) was measured in millimeters squared (mm\^2). Data from both eyes were averaged for each participant for analysis. A positive change from Baseline indicated fuller eyelashes (improvement).

Percentage of Participants Satisfied or Very Satisfied in the Patient's Assessment of Overall Eyelash Satisfaction as Measured by the Eyelash Satisfaction Questionnaire (ESQ-9)Month 4

Participants rated their overall eyelash satisfaction by answering Eyelash Satisfaction Questionnaire (ESQ-9) question #3: "Overall, how satisfied are you with your eyelashes?" using a 5-point scale: 1= very unsatisfied (worst), 2= unsatisfied, 3= neutral, 4= satisfied or 5= very satisfied (best). The percentage of participants who rated their satisfaction as satisfied or very satisfied at Month 4 is reported.

Change From Baseline in Upper Eyelash Intensity (Darkness) as Measured Using DIABaseline, Month 4

Photographs were taken of the eyelashes and assessed using DIA. Eyelash darkness (intensity) was measured in both eyes and averaged for analysis using a scale where 0=black and 255=white. A negative change from Baseline indicated darker eyelashes (improvement).

Change From Baseline in Upper Eyelash Length as Measured Using Digital Image Analysis (DIA)Baseline, Month 4

Photographs were taken of the eyelashes and assessed using DIA. Length was measured in millimeters (mm). Data from both eyes were averaged for each participant for analysis. A positive change from Baseline indicated longer length (improvement)

© Copyright 2025. All Rights Reserved by MedPath